Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

Part C - Update Notes, plus an Institutional Ownership Revision

|Includes: Rock Creek Pharmaceuticals, Inc. (RCPI)

Dr. John L. Faessel


Commentary and Insights


Star Scientific Inc. (CIGX) Nasdaq


A Stock for the Ages – Maybe? Likely!


Part C:


Update Notes, plus an Institutional Ownership Revision


As you may know I was an attendee at the Roskamp meeting in Sarasota Florida on June 1 where much of the research at the Roskamp Institute, Johns Hopkins and Flint Michigan was discussed and demonstrated with videos and extensive slide shows during the four-hour presentation. 


Two important peer review studies that I understand are complete are due to be published in medical journals shortly, I believe: Note; these already submitted studies would not be published by Star, but by medical publications that have their own review process, timetable, addenda and exact timing is always an unknown.  


·       Alzheimer related: Roskamp's director of research Dr. Michael Mullan announced at the June 1 meeting that a “peer-review was being readied for publication.” The mouse studies that were demonstrated and referenced at the meeting are completed and I believe that at any time this dramatic study in Alzheimer's will be published in one of the nation’s important medical.


Dr. Mullan played videos showing once-Alzheimer’s-afflicted mice beginning not only to remember again, but becoming able to add critical new information to the cognitive equation and, thus, to change behavior so as even to improve their lot. That’s impossible for a “demented” mouse. A split screen video depicted a mouse fully impaired with the diseased for comparison. He went on to say that CRP* levels also fell 50% in these test animals, indicating less inflammation. Dr. Mullan called the research “profound.”


In my opinion the publication of this peer-review study will gain significant worldwide press. To date, there's been no equivalent treatment that would restore the cognitive ability of mice, or humans for that matter. Alzheimer’s is projected to cost $20 trillion over the next 40 years. This peer-review could have profound reach and importance for Alzheimer's treatment.


·       Thyroid research: Two prominent Johns Hopkins Professors of Medicine presented at the Roskamp meeting: widely known and acclaimed endocrinologist Dr. Paul Ladenson, and internationally known Dr. Patrizo Caturegli spoke of their research on RCP-006 in stopping thyroiditis in humans. Significantly, Dr. Ladenson in his final comments at the meeting said that, “Aside from RCP-006 (think Anatabloc) there is no known compound that stops thyroiditis.” 


I understand that this part of above referenced Johns Hopkins thyroid study is also complete, has been submitted to peer review and that shortly the results from this testing will be published in one of the medical journals.


Twenty (20) million Americans suffer from thyroiditis. Impact on the shares of Star Scientific will be great when this research is published. Again; “Aside from RCP-006 there is no known compound that stops thyroiditis.”




There is another just announced (8/9/2011) new human trial examining the role of RCP-006 on thyroid disease to be conducted at the University of Pisa, Medical School, Pisa, Italy. This study of 500 participants is being shepherded by Dr. Patrizio Caturegli of Johns Hopkins.


Also of Note: “Johns Hopkins was thought to be researching Stars RCP-006 in the fields of thyroid, arthritis, some cancers and other conditions; importantly, we now know that they are.” Patrick Cox - Breakthrough Technologies


·       Star is awaiting a decision from the US Court of Appeals for the Federal Circuit on its appeal of the jury verdict in its patent infringement trial against RJ Reynolds Tobacco Company (NYSE:RAI). Oral argument on the appeal took place on January 11, 2011, and the Federal Circuit Court generally attempts to issue rulings within four to six months following oral argument.


·       Institutional ownership continues to increase for (CIGX). Currently, about 111 financial institutions hold about 40% of the shares. That’s up from 91 institutions the last reporting period. Last November insiders and 5% holders bought an “additional” $14 million worth of shares plus warrants, with a 6-month lock-up. On 3/19/2011 Star CEO Jonnie Williams bought 500,000 shares of the company's stock for $1.97 according to securities filings. Hedge fund Tradewinds Investment Management, a more that 16% shareholder of Star, also picked up another 1,000,000 shares at $1.84 per on the same day to now total 20.3 million shares.


If you missed my previous reports—more specific in detail and scope on each of these themes—or wish to receive my Best Ideas for 2011, send a request to:


I have bought shares of Star Scientific in the open market and have no other affiliation with the company than as a shareholder.